SOAT1 and Erythema: JAK inhibitors can attenuate the local inflammatory response, modulate immunity, and ameliorate vascular dysfunction and lymphatic reflux disorders by inhibiting the JAK-STAT signalling pathway that may lead to an improvement in the facial erythema and oedema of the patient.